Advertisement

European Journal of Nuclear Medicine

, Volume 20, Issue 2, pp 130–137 | Cite as

Iodine-123-labelled serum amyloid P component scintigraphy in amyloidosis

  • Rachid Saïle
  • Marc Deveaux
  • Eric Hachulla
  • Jacques Descamps
  • Bernard Duquesnoy
  • Xavier Marchandise
Original Article

Abstract

This study describes the results of scintigraphy with iodine-123-labelled serum amyloid P component (SAP) as a means of establishing the distribution of organ involvement in amyloidosis. The significance of 123I-SAP scans obtained in 15 patients with biopsy-proven AA or AL amyloidosis is discussed. Biopsy-proven amyloidosis was typically confirmed by scintigraphy, though such confirmation was not obtained in the kidneys in six patients with histological proof of extensive renal amyloid deposition. This lack of uptake may have been due to the accumulation of a major part of the 123I-SAP in the spleen and/or liver. Twenty-four hour whole-body retention of 123I-SAP was higher in patients with amyloidosis than in controls. Twenty-four hour tracer accumulation of the radioactivity in the extravascular compartment was notably greater in patients than in controls and appeared to be a good diagnostic criterion. We conclude that 123I-SAP scintigraphy may be helpful for the evaluation of organ involvement not only in patients with biopsy-proven amyloidosis but also when a biopsy cannot be performed or when a strong suspicion of amyloidosis exists in spite of repeated negative biopsises.

Key words

Amyloidosis Serum amyloid P component Scintigraphy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Amir J, Kessler E, Devries A (1971) Skin and mucosal hemorrhage of prolonged duration in systemic amyloidosis. Blood 37:530–533.Google Scholar
  2. Coe JE (1982) Female protein of the Syrian hamster: a homology of C-reactive protein. Ann N Y Acad Sci 389:299–307.Google Scholar
  3. Cohen AS (1967) Amyloidosis. N Engl J Med 277:628–638.Google Scholar
  4. Cohen AS, Connors LA (1987) The pathogenesis and biochemistry of amyloidosis. J Pathol 151:1–10.Google Scholar
  5. De Beer FC, Pepys MB (1982) Isolation of human C-reactive protein and serum amyloid P component. J Immunol Methods 50:17–31.Google Scholar
  6. Eriksson P, Backman C, Bjerle P, Eriksson A, Holm S, Olofsson BO (1984) Non-invasive assessment of the presence and severity of cardiac amyloidosis; a study of familial amyloidosis with polyneuropathy by cross sectional echocardiography and technetium-99m pyrophosphate scintigraphy. Br Heart J 52:321–326.Google Scholar
  7. Falk RH, Lee VW, Rubinow A, Hood WB Jr, Cohen AS (1983) Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol 51:826–830.Google Scholar
  8. Fitzmaurice RJ, Bartley C, McClure J, Ackrill P (1991) Immunohistological characterization of amyloid deposits in renal biopsy specimens. J Clin Pathol 44:200–204.Google Scholar
  9. Floege J, Burchert W, Brandis A et al. (1990) Imaging of dialysis-related amyloid (AB-amyloid) deposits with 131-I-β2-microglobulin. Kidney Int 38:1169–1176.Google Scholar
  10. Furie B, Li Ann Voo BS, McAdam KPWJ, Furie BC (1981) Mechanism of factor X deficiency in systemic amyloidosis. N Engl J Med 304:827–830.Google Scholar
  11. Gejyo F, Yamada T, Odani S et al. (1985) A new form of amyloid protein associated with chronic haemodialysis was identified as β2-microglobulin. Biochim Biophys Res Commun 129:701–706.Google Scholar
  12. Gertz MA, Kyle RA, Greipp PR (1983) Hyposplenism in primary systemic amyloidosis. Ann Intern Med 98:475–477.Google Scholar
  13. Gertz MA, Brown ML, Hanser MF, Kyle RA (1987) Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis. Arch Intern Med 147:1039–1044.Google Scholar
  14. Glenner GG (1980a) Amyloid deposits and amyloidosis — the β-fibrilloses I. N Engl J Med 302:1283–1292.Google Scholar
  15. Glenner GG (1980b) Amyloid deposits and amyloidosis — the β-fibrilloses II. N Engl J Med 302:1333–1343.Google Scholar
  16. Gorevic PD, Casey TT, Stone WJ, Di Raimondo CR, Prelli FC, Frangione B (1985) Beta-2-microglobulin in an amyloidogenic protein in man. J Clin Invest 76:2425–2429.Google Scholar
  17. Hardouin P, Flipo RM, Foissac-Gegoux P et al. (1987) Current aspects of osteoarticular pathology in patients undergoing hemodialysis: study of 80 patients. J Rheumatol 14:780–787.Google Scholar
  18. Hawkins PN, Lavender JP, Myers HP, Pepys M (1988) Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet I:143–148.Google Scholar
  19. Hawkins PN, Lavender JP, Pepys MB (1990) Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 323:508–513.Google Scholar
  20. Hind CRK, Gibson DG, Lavender JP, Pepys MB (1986) Noninvasive technique for demonstrating cardiac involvement in the acquired forms of systemic amyloidosis. In: Glenner GG, Osserman EF, Benditt EP, Calkins E, Cohen AS, Zucker-Franklin D (eds) Amyloidosis. Plenum, New York, pp 617–620.Google Scholar
  21. Horowitz B, Wiebe ME, Lippin A, Stryker MH (1985) Inactivation of viruses in labile blood derivatives. 1-Disruption of lipid enveloped viruses by tri (n-butyl) phosphate detergent combination. Transfusion 25:516–522.Google Scholar
  22. Janssen S, Van Rijswijk MH, Piers DA, De Jong GMT (1984) Soft tissue uptake of 99m-Tc-diphosphonate in systemic AL amyloidosis. Eur J Nucl Med 9:538–541.Google Scholar
  23. Janssen S, Piers DA, Van Rijswijk MH, Meijer S, Mandema E (1990) Soft tissue uptake of 99m Tc-diphosphonate and 99m Tc-pyrophosphate in amyloidosis. Eur J Nucl Med 16:663–670.Google Scholar
  24. Johnston JB, Rayner HL, Trevemen C, Greeberg D (1982) Skeletal uptake of Tc-99m-pyrophosphate in amyloidosis. Am J Hematol 13:247–251.Google Scholar
  25. Kyle RA, Bayrd ED (1975) Amyloidosis: review of 236 cases. Medicine 54:271–299.Google Scholar
  26. Maury CJ (1984) Reactive (secondary) amyloidosis and its pathogenesis. Rheumatol Int 5:1–7.Google Scholar
  27. Noel LH, Droz D, Ganeval D (1987) Immunohistochemical characterization of renal amyloidosis. Am J Clin Pathol 87:756–761.Google Scholar
  28. Ohta H, Endo K, Kanho Y et al (1989) Technetium-99m (V) DMSA uptake in amyloidosis. J Nucl Med 30:2049–2052.Google Scholar
  29. Painter RH, De Escallon I, Massey A, Pinteric L, Stern SB (1982) The structure and binding characteristics of serum amyloid protein (9.5 S alpha 1 glycoprotein). Ann N Y Acad Sci 389:199–215.Google Scholar
  30. Pepys MB, Baltz ML (1983) Acute phase proteins is with special reference to C-reactive protein and related protein (pentraxins) and serum amyloid A protein. Adv Immunol 34:141–212.Google Scholar
  31. Pepys MB, Dyck RF, De Beer FC, Skinner M, Cohen AS (1979) Binding of serum amyloid P component (SAP) by amyloid fibrils. Clin Exp Immunol 38:284–293.Google Scholar
  32. Pinteric L, Painter RH (1979) Electron microscopy of serum amyloid protein in the presence of calcium: alternative forms of assembly of pentagonal molecules in two-dimensional lattices. Can J Biochem 57:727–736.Google Scholar
  33. Richardson AP, Mountford PJ, Baird AC, Heyderman E, Richardson TC, Coakley AJ (1986) An improved iodogen method of labelling antibodies with 123I. Nucl Med Commun 7:355–362.Google Scholar
  34. Saïle R, Delpierre C, Puchois P et al. (1988) Enzyme linked immunosorbent assay for human serum amyloid A with use of specific antibodies against synthetic peptide. Biochim Clin Chem 34:1667–1771.Google Scholar
  35. Saïle R, Hocke G, Tartar A, Fruchart JC, Steinmetz A (1989) Antipeptide antibodies discriminate between different SAA proteins in human plasma.Biochim Biophys Acta 992:407–408.Google Scholar
  36. Saïle R, Kandoussi A, Deveaux M, Descamps J, Hachulla E, Cachera C (1991) Quantitation of serum amyloid P by enzyme linked immunosorbent assay. Clin Chem 37:1742–1745.Google Scholar
  37. Stone MJ, Hirsch VJ (1986) Splenic function in amyloidosis. In: Glenner GG, Osserman EF, Benditt EP, Calkins E, Cohen AS, Zucker-Franklin D (eds) Amyloidosis. Plenum, New York, pp 583–590.Google Scholar
  38. Van Antwerp JD, O'Mara RE, Pitt MJ, Walsh S (1979) Technetium-99m diphosphonate accumulation in amyloid. J Nucl Med 16:238–240.Google Scholar
  39. Yood RA, Skinner M, Rubinow A, Talarico L, Cohen AS (1983) Bleeding manifestations in 100 patients with amyloidosis. J Am Med Assoc 249:1322–1324.Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Rachid Saïle
    • 1
  • Marc Deveaux
    • 1
  • Eric Hachulla
    • 2
  • Jacques Descamps
    • 3
  • Bernard Duquesnoy
    • 4
  • Xavier Marchandise
    • 1
  1. 1.Service Associé de Médecine Nucléaire, Hôpital Claude HuriezCentre Hospitalier UniversitaireLille CedexFrance
  2. 2.Service de Médecine Interne, Hôpital Claude HuriezCentre Hospitalier UniversitaireLille CedexFrance
  3. 3.Centre Régional de Transfusion SanguineLille CedexFrance
  4. 4.Service de Rhumatologie, Hôpital BCentre Hospitaller UniversitaireLille CedexFrance

Personalised recommendations